A Chinese broker (China Post Securities) issued a strongly bullish note on MicroPort MedBot (2252.HK), highlighting that global commercial orders for its Toumai surgical robot surpassed 300 units as of June 16, 2026, up from 220 units in March 2026 and 160 units in December 2025. The broker calls the stock an excellent buying opportunity and strongly recommends it.
MicroPort MedBot's accelerating global commercialization and expanding product portfolio make it a strong buy, according to the broker.
Free preview — more China A-share & HK research · About Us · Legal & Privacy